ENGN

WBB Securities initiated coverage of enGene Therapeutics with a rating of Buy and set a new price target of $21.50

8-K - enGene Therapeutics Inc. (0001980845) (Filer)

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ

S-8 - enGene Holdings Inc. (0001980845) (Filer)

424B5 - enGene Holdings Inc. (0001980845) (Filer)

8-K - enGene Holdings Inc. (0001980845) (Filer)

10-Q - enGene Holdings Inc. (0001980845) (Filer)

8-K - enGene Holdings Inc. (0001980845) (Filer)

LEGEND pivotal cohort update planned for a spring 2026 medical conference 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026 Biologics License Application (BLA) submission for detalimogene planned for 2H 2026 Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028 Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter en

EFFECT - enGene Holdings Inc. (0001980845) (Filer)

enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Format: Presentation Time: 1:20 p.m. ET Leerink Partners 2026 Global Healthcare Conference Date: Monday, March 9, 2026 Format: Fireside chat Time: 8:00 a.m. ET Barclays 28th Annual Global Healthcare Conference Date: Tuesday, March 10, 2026 Format: Fireside chat Time: 9:00 a.m. ET Citizens Life Sciences Conference Date: Wednesday, March 11, 2026 Format: Fireside chat Time: 1:40 p.m. ET A live webcast of these even

S-3 - enGene Holdings Inc. (0001980845) (Filer)

10-K/A - enGene Holdings Inc. (0001980845) (Filer)

SCHEDULE 13G/A - enGene Holdings Inc. (0001980845) (Subject)

SCHEDULE 13G - enGene Holdings Inc. (0001980845) (Subject)

SCHEDULE 13G/A - enGene Holdings Inc. (0001980845) (Subject)

enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live webcast of the fireside chat can be accessed on the "Events and Presentations" page under the "Investors" section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of cr

4 - enGene Holdings Inc. (0001980845) (Issuer)

4 - enGene Holdings Inc. (0001980845) (Issuer)

4 - enGene Holdings Inc. (0001980845) (Issuer)

4 - enGene Holdings Inc. (0001980845) (Issuer)

4 - enGene Holdings Inc. (0001980845) (Issuer)

4 - enGene Holdings Inc. (0001980845) (Issuer)

4 - enGene Holdings Inc. (0001980845) (Issuer)

4 - enGene Holdings Inc. (0001980845) (Issuer)